Dr. Reddy’s Secures DCGI Approval for Zytorvi in Advanced Esophageal Cancer
Dr Reddys Laboratories Ltd · Press Release · 21 Oct 2026, 3:09 pm
Dr. Reddy’s Secures DCGI Approval for Zytorvi in Advanced Esophageal Cancer Dr. Reddy’s Laboratories received DCGI approval for Zytorvi (toripalimab), in combination with cisplatin and paclitaxel, as a first-line treatment for advanced esophageal squamous cell carcinoma (ESCC) regardless of PD-L1 biomarker status. This marks Zytorvi's second approved indication in India, following nasopharyngeal carcinoma. Phase 3 JUPITER-06 trial data showed the regimen reduced disease or death risk by 42%, extending median overall survival to 17.7 months versus 12.9 months for chemotherapy alone. Dr. Reddy’s holds exclusive licensing rights for toripalimab across 21 countries.
Original exchange filing (PDF)
More announcements from Dr Reddys Laboratories Ltd
- Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 · 14 Nov 2026
- Intimation of Analyst meet · 11 Nov 2026
- Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 · 05 Nov 2026
- Allotment of Employee Stock options · 04 Nov 2026
- Clarification - Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 · 04 Nov 2026
- The Exchange has sought Clarification from Dr Reddys Laboratories Ltd with reference to the media report appearing on https://www.firstpost.com dated November 03, 2026 (Link : https://www.firstpost.com/business/indias-dr-reddys-gets-us-nod-for-40-generic-hiv-prevention-shot-for-120-poorer-countries-14057224.html) .... · 03 Nov 2026
- Transcript of Earnings call · 30 Oct 2026
- Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 · 28 Oct 2026
